Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
0(0%)
Results Posted
71%(5 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_1
2
20%
Ph phase_2
8
80%

Phase Distribution

2

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
8(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(7)
Terminated(2)
Other(1)

Detailed Status

Completed7
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
77.8%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (20.0%)
Phase 28 (80.0%)

Trials by Status

unknown110%
terminated220%
completed770%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

NCT02757885
completedphase_2

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

NCT01572662
completedphase_1

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

NCT02799147
completedphase_2

Allogeneic Transplantation For Severe Osteopetrosis

NCT00775931
terminatedphase_2

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

NCT02627573
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02757885Phase 2

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

Completed
NCT01572662Phase 2

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Completed
NCT02799147Phase 1

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Completed
NCT00775931Phase 2

Allogeneic Transplantation For Severe Osteopetrosis

Completed
NCT02627573Phase 2

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Terminated
NCT02806375Phase 1

PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis

Completed
NCT01279616Phase 2

A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

Terminated
NCT02294552Phase 2

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

Completed
NCT00176878Phase 2

Stem Cell Transplant for Bone Marrow Failure Syndromes

Completed
NCT02776202Phase 2

HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10